At-Home Gait Assessment
A Wearable Remote Data Capture Solution for Home-Based Gait Assessment in Multiple Sclerosis
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Luis Fernandez, MS
- Phone Number: 929-455-5090
- Email: Luis.Fernandez2@nyulnagone.org
Study Contact Backup
- Name: Giuseppina Pilloni, PhD
- Email: Giuseppina.pilloni@nyulangone.org
Study Locations
-
-
New York
-
New York, New York, United States, 10016
- NYU Langone Health
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Ages 18-70 years old (inclusive)
- Confirmed diagnosis of MS (any MS subtypes, Relapsing Remitting [RR], Primary Progressive [PP], or Secondary Progressive [SP])
- PDSS score from 0 to 5
- Stable and continuous access to internet at home
- Adequate home facilities (enough space, quiet and distraction free area)
- Ability to provide informed consent.
Exclusion Criteria:
- Below average estimated premorbid cognitive functioning (based on WRAT-4 reading recognition standard z-score < 85).
- Presence of severe cognitive impairment (based on SDMT age normative z-score < -3.0).
- Presence of primary neurological disorders other than MS or primary psychiatric disorder that would influence ability to complete assessments.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Adults with MS
Participants will complete an in-clinic visit (self-reported outcome of MS disability, a standard walking clinical evaluation, and a sensor-based gait evaluation) and 3 remote supervised self-administered gait assessments using the MS-GRCA system.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean Gait Velocity
Time Frame: Up to Week 4
|
Measured using sensor-based gait assessment
|
Up to Week 4
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean Stride Length
Time Frame: Up to Week 4
|
Measured using sensor-based gait assessment at baseline and remote visits 1, 2 and 3.
|
Up to Week 4
|
|
Mean Double Support Duration
Time Frame: Up to Week 4
|
Double support duration represents the time that both feet are on the ground while walking.
Measured using sensor-based gait assessment at baseline and remote visits 1, 2 and 3.
|
Up to Week 4
|
|
Mean Stance Duration
Time Frame: Up to Week 4
|
Stance duration represents the duration of the time between heel strike and toe off of the same foot.
Measured using sensor-based gait assessment at baseline and remote visits 1, 2 and 3.
|
Up to Week 4
|
|
Mean Cadence
Time Frame: Up to Week 4
|
Cadence defined as number of steps per minute.
Measured using sensor-based gait assessment at baseline and remote visits 1, 2 and 3.
|
Up to Week 4
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Leigh Charvet, PhD, NYU Langone Health
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 22-00375
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
NCT05177523RecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)
-
NCT01466114UnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple Sclerosis
-
NCT01917019CompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent Progressive
-
NCT07006805Not yet recruitingProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
NCT00813969CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple Sclerosis
-
NCT04688788Active, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis
-
NCT02549703CompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis
-
NCT04940065CompletedRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple Sclerosis
-
NCT02495766CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis
-
NCT00559702CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis